Asset sale Pending

SERB Pharmaceuticals acquisition of Exclusive development and commercialisation rights to Idefirix in Europe and MENA

€115m consideration

Announced 19 May 2026

Advisers

Exclusive development and commercialisation rights to Idefirix in Europe and MENA

Target

Not disclosed

Target
Exclusive development and commercialisation rights to Idefirix in Europe and MENA
Acquirer
SERB Pharmaceuticals
Seller
Hansa Biopharma AB
Buyer based in
France
Seller based in
Sweden (unverified)
Sector
Pharma
Tags
Pharma, Rare Disease

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.